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Abstract 
We recently demonstrated that blockade of the mineralocorticoid receptor (MR) effectively 
ameliorated GC-induced skin atrophy in healthy human skin explants and epidermal MR knock-
out mice. However, whether MR blockade improves the therapeutic index of GCs in skin 
pathology was not investigated.  
We assessed the effects of GCs, MR antagonists (MRA), or both, in SDS-treated human skin 
explants. All treatments restored SDS-augmented epidermal thickness but only GC plus MRA 
restored the expression of COL1A1. However, MRA alone or in combination with GCs may 
exert a dual role in regulating inflammatory cytokines. Thus, although combined treatment may 
be beneficial to improve irritative skin, extensive in vivo testing is required to establish whether 
the anti-inflammatory effects of GCs are maintained in the presence of MRA.  
 
Background 
Skin inflammatory diseases are commonly treated with topical glucocorticoids (GCs) because 
their anti-proliferative and anti-inflammatory effects (1). However, their use is limited due to 
adverse side effects such as skin atrophy characterized by tissue thinning caused by inhibition of 
keratinocyte and fibroblast proliferation and a reduction in the collagen synthesis (1,2). Also, 
local steroidogenic activity is key to homeostatic prevention or attenuation of skin pathology 
(3,4). 
GCs bind and activate two closely related receptors, the GC receptor (GR) and the 
mineralocorticoid receptor (MR). Our recent work using genetic and pharmacological 
approaches in mouse skin and healthy skin of volunteers and human skin explants has shown 
that MR inactivation ameliorates GC-induced skin atrophy (5,6). In both settings, MR blockade 
improved the epidermal thinning partially reversing the keratinocyte proliferation inhibition 
induced by topical GC treatments (5,6). However, GCs similarly reduced Col1a1 mRNA levels 
in MR epidermal knock-out and control mice indicating that inactivation of dermal MR is also 
necessary for the effective reversion of skin atrophy (5).  
 
Questions addressed 
We have analyzed whether GC treatment combined with pharmacological MR inhibition 
achieves a better therapeutic index in an irritative model in human skin explants.  
 
Experimental design 
Human skin explants culture and treatments 
Human skin biopsies were obtained from three different subjects. After adipose tissue excision, 
6 mm full-thickness punches were obtained of each subject, placed in organotypic culture 
floating with the dermis embedded into the medium, and used for one independent experiment. 
Human skin explants were cultured in medium DMEM 1x with GlutaMAX, 10% charcoal-
stripped fetal bovine serum and 1% Penicilin/Streptomicin, and incubated at 37ºC, 5% CO2 (6). 
SDS (15 µg/ml; Merck, Darmstadt, Germany) was added to the medium during 3 days; then, 
washed, and explants were treated with 100 nM clobetasol propionate, 10 μM canrenoate, 100 
nM clobetasol plus 10 μM canrenoate (Sigma, St Louis, MO), or vehicle, during 4 days. 
 
Results  
Using human skin explants, we have mimicked an irritative pathology by adding SDS to the 
medium (7). After 3 days, SDS-induced tissue damage was revealed in hematoxylin-eosin 
stained sections by cell ballooning (Fig.1a, arrows), increased dermal cellularity (Fig.1a) and 
augmented epidermal thickness (Fig.1a,b). These features were similar to those observed in 
human skin topically treated with SDS (8,10). However, SDS did not affect collagen deposition 
or mRNA expression levels relative to vehicle-treated samples (Fig.s1a,b). 
We assessed the therapeutic effectiveness of the GC clobetasol, the MRA canrenoate, or both, in 
skin explants incubated with SDS. Clobetasol improved the SDS-induced effects by reducing 
cell ballooning, dermal cellularity, and epidermal thickness (Fig.1a,b). As expected, clobetasol 
also reduced collagen deposition as shown by the Masson trichrome staining and the 70% 
reduction in COL1A1 mRNA levels (Fig.s1a,b). Treatment with canrenoate elicited similar 
effects than GCs in terms of epidermal thickness and COL1A1 expression, with a reduction of 
approximately 60% in both parameters (Fig.1a,b; s1a,b). This is consistent with previous data 
reporting that the induced expression of COL1A1 in human dermal fibroblast was effectively 
blocked by treatment with the MRA spironolactone (9). Importantly, the combined treatment 
using clobetasol and canrenoate was also effective in decreasing the SDS-induced epidermal 
thickening (Fig.1a,b). In addition, this treatment was the only that improved the collagen 
deposition and the COL1A1 mRNA levels as compared to each compound used separately (Fig. 
s1a,b). 
We also evaluated the expression of keratin (K)6, a marker of keratinocyte hyperproliferation 
that is found in healthy palmar and plantar skin as well as diseased skin, in explants treated with 
SDS alone or in combination with the indicated compounds. After SDS treatment, all epidermal 
layers stained positive for K6; this expression was significantly reduced by clobetasol, which 
was confined to the upper epidermal layers, but unaffected by canrenoate (Fig.2a). The 
combined treatment reduced the effectiveness of clobetasol alone as it produced an intermediate 
effect with K6 being expressed in several suprabasal layers (Fig.2a). These results suggest that 
complete K6 inhibition by GCs requires functional MR. 
Next, we assessed whether the anti-inflammatory effects of GCs were preserved after blocking 
MR. We analyzed the expression of the pro-inflammatory cytokines IL-6 and IL1A and a key 
enzyme in prostaglandin biosynthesis, COX-2, which are up-regulated after SDS treatment in 
human keratinocytes (11) or skin (8,12). Clobetasol significantly reduced the expression of 
SDS-induced IL-6, IL1A, and COX-2 mRNA levels, as expected (Fig.2b). However, canrenoate 
triggered both anti-inflammatory effects, with decreased expression of IL-6 and COX-2, and 
also pro-inflammatory, with up-regulation of IL1A mRNA levels (Fig.2b). The use of clobetasol 
plus canrenoate resulted in attenuated or lack of repression of IL-6 and IL1A, respectively, while 
it had no effect in the inhibition of COX-2 relative to clobetasol alone (Fig.2b). Also, consistent 
with its reported induction by GCs (13), Clobetasol up-regulated the mRNA levels of the anti-
inflammatory cytokine IL-10 in SDS-treated skin explants (Fig. 2b). While canrenoate did not 
affect IL-10 mRNA levels, clobetasol plus canrenoate resulted in a trend towards increased 
transcript levels without reaching statistical significance, suggesting that MR blockade affects 
GC-dependent induction of IL-10. These results show that MR may exert a dual role in skin 
inflammation. 
 
Conclusions 
SDS-treatment in human skin explants induced tissue damage as demonstrated by cell 
ballooning, increased epidermal thickening and dermal cellularity. In this clinically relevant 
setting, MRA alone was as effective as GCs in normalizing epidermal thickness although it was 
unable to control up-regulation of K6 expression and exerted dual pro- and anti-inflammatory 
actions. The combined use of GCs plus MRA had several advantages relative to individual 
treatments since it restored epidermal thickness, partially reversed K6 up-regulation, and 
normalized collagen deposition. However, in this model of human diseased skin, the anti-
inflammatory effects of GCs, in the case of IL6 and IL1A, were not fully preserved in the 
presence of MRAs. Overall, our data show that addition of MRA to GCs may be beneficial to 
improve irritative skin, but extensive in vivo testing is required to establish whether the anti-
inflammatory effects of GCs are maintained in the presence of MRA. 
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Figure legends 
Figure 1. Combined treatment using GCs (Clobetasol) and MR antagonists (Canrenoate) 
in human skin explants confers an overall protection against SDS-induced skin damage. 
a) H&E staining of human skin explants treated with vehicle only or SDS plus vehicle (V), 
clobetasol (Clobe), canrenoate (Canre), or Clobe+Canre. Broken lines separate 
epidermis from dermis. Arrows indicate cell ballooning of suprabasal keratinocytes 
induced by SDS. Bar: 50 µm. 
b) Epidermal thickness quantitation was assessed in the same groups as in a). ANOVA, 
post hoc Tukey test: n=3 of each treatment, *** p<0.001, differences versus vehicle 
only; ### p<0.001, differences versus SDS+V; + p<0.05, differences between other 
treatments.  
Figure 2. Epidermal damage induced by SDS in human skin explants is not completely 
restored by Clobetasol upon MR pharmacological blockade. 
a) Immunohistochemistry for K6 of human skin explants treated with SDS plus vehicle 
(V), clobetasol (Clobe), canrenoate (Canre), or Clobe+Canre. Broken lines separate 
epidermis from dermis. Bar: 50 µm. 
b) Relative mRNA levels of IL-6, IL1A, COX-2, and IL-10, were assessed by RT-qPCR in 
the same groups as in a). ANOVA, post hoc Tukey test: n=3 of each treatment, * 
p<0.05, ** p<0.05, *** p<0.001, differences versus V; # p<0.05, ## p<0.01, ### 
p<0.001, differences between other treatments.  
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Supplementary Information  
 
Supplementary Materials and Methods 
 
Skin samples 
Human skin was obtained from patients subjected to surgery. Patients were informed and had no 
objection that the skin discarded from surgery could be used for research purposes. Written 
patient consent was not required because French law considers that it is not mandatory for non-
interventional biological collection for immunological and molecular research. This procedure 
was approved by the Comité de Protection des Personnes Ile de France V.  
Sample processing, and histological analysis 
After the treatments, each sample was divided in two parts. One was frozen at -80ºC for RNA 
isolation and RT-qPCR, and the other was fixed in 70% ethanol followed by paraffin 
embedding. 4 µm skin sections were obtained and stained with hematoxylin-eosin, and 
Masson’s trichrome (Sigma, St Louis, MO), or used for K6 immunohistochemistry (PRB-169P, 
Biolegend, San Diego, CA), as described (5). Epidermal thickness measurement was performed 
using the software IMAGE J (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland). At least five photomicrographs were taken of each section and at least 
five measurements were taken from each photomicrograph using a Leica DM1000 microscope, 
a Leica EC3 camera and Leica LAS EZ software (Leica Microsystems, Wetzlar, Germany).  
RNA isolation and RT-qPCR 
RNA was isolated using Trizol (Thermo Fisher, Thermo Fisher Scientific, Waltham, MA) and 
reverse transcribed using oligo-dT and RevertAid H-minus Reverse Transcriptase (Fermentas 
Inc., Burlington, Canada). qPCR was conducted using specific oligonucleotides (Table 1) and 
FastStart Universal SYBR Green Master ROX (Roche) in an Applied Biosystems 7500 Fast real 
time PCR system, as described (5). Data were normalized to RPLP0 expression. 
Table 1. RT-qPCR primers. 
Gene symbol  Forward sequence 5'→ 3' Reverse sequence 5'→ 3' product bp 
COL1A1 GAGGGCCAAGACGAAGACATC CAGATCACGTCATCGCACAAC 140 
IL-6 GGTACATCCTCGACGGCATCT GTGCCTCTTTGCTGCTTTCAC   81 
IL1A TGGTAGTAGCAACCAACGGGA ACTTTGATTGAGGGCGTCATTC 215 
COX-2 CAGAGTTGGAAGCACTCTATGG CTGTTTTAATGAGCTCTGGATC 306 
IL-10 GTGGAGCAGGTGAAGAATGC GCCACCCTGATGTCTCAGTT 137 
RPLP0 AGATGCAGCAGATCCGCAT GTTCTTGCCCATCAGCACC   59 
 
Statistical Analysis 
Experimental data were analyzed using IBM SPSS Statistics 23 software as described (5). In all 
graphs, mean values ± SD are shown. Prior to parametric testing, data were subjected to 
logarithmic transformation. For comparisons among more than two experimental groups, we 
used the one-way ANOVA which if statistically significant was followed by a post hoc Tukey 
multiple comparison test. p values less than 0.05 were considered statistically significant. 
 Supplementary Figures 
 
Supplementary Fig. 1. Combined use of Clobetasol and MRA Canrenoate in human skin 
explants improved the collagen deposition and the COL1A1 mRNA levels relative to individual 
treatments. 
a) Masson trichromic staining of human skin explants treated with vehicle only or SDS 
plus vehicle (V), clobetasol (Clobe), canrenoate (Canre), or Clobe+Canre. Broken lines 
separate epidermis from dermis. Bar: 50 µm. 
b) Relative COL1A1 mRNA levels were assessed by RT-qPCR in all groups in a). 
ANOVA, post hoc Tukey test: n=3 of each treatment, * p<0.05, ** p<0.01, differences 
versus vehicle only; # p<0.05, ## p<0.01, differences versus SDS+V. 
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